FY2024 Earnings Estimate for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Research analysts at HC Wainwright issued their FY2024 earnings per share estimates for Corvus Pharmaceuticals in a research note issued on Thursday, January 2nd. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of ($0.41) for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

A number of other equities analysts have also recently weighed in on the stock. LADENBURG THALM/SH SH upped their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Finally, Oppenheimer increased their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $6.03 on Monday. The business’s 50 day moving average price is $7.62 and its 200-day moving average price is $5.36. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The firm has a market capitalization of $387.47 million, a price-to-earnings ratio of -6.48 and a beta of 1.07.

Institutional Trading of Corvus Pharmaceuticals

Several large investors have recently bought and sold shares of CRVS. Nwam LLC acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $53,000. XTX Topco Ltd purchased a new position in Corvus Pharmaceuticals during the third quarter worth approximately $74,000. Virtu Financial LLC purchased a new position in Corvus Pharmaceuticals during the third quarter worth approximately $83,000. Avity Investment Management Inc. boosted its stake in Corvus Pharmaceuticals by 138.2% during the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after buying an additional 16,000 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at $89,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.